anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Acute myocardial infarction (AMI) is a major cause of morbidity and mortality worldwide. In real clinical practice, early and accurate recognition of AMI is crucial to accelerate effective reperfusion therapy. High-sensitivity cardiac troponin T (hs-cTnT) is an important protein that regulates cardiomyocytes excitability, which can be proliferated in cardiomyocytes and released into the blood after myocardial injury or infarction. According to the fourth universal definition of AMI, a rise and/or fall of cTn values with at least one value above the 99th percentile URL is the essential precondition for diagnosing AMI. However, it is challenging for clinicians to diagnose AMI in patients with elevated hs-cTnT levels before a rise and/or fall of hs-cTnT values can be observed, particularly for those who present atypical symptoms and non-significant changes in electrocardiograms (ECG). When the 99th percentile upper reference limit (URL) is referred, it happens frequently that the elevations of hs-cTnT are not caused by AMI, but by other cardiac or even non-cardiac diseases. Therefore, thresholds above the 99th percentile have been proposed to improve the specificity and to accelerate the rule in of myocardial infarction.

This study aimed to find a higher and more accurate cut-off value of hs-cTnT to rule in AMI in a large volume of patients with elevated hs-cTnT.
When a medical device includes one type and two types, the medical device is of the two types. When a medical device includes two types and three types, the medical device belongs to three types. By analogy, the same conclusion can be reached. With the development of electronic technology, various simple household medical appliances such as thermometers, stethoscopes, sphygmomanometers and the like are continuously on the market, and automatic and semi-automatic electronic household medical appliances such as electronic sphygmomanometers, blood glucose testers, electronic thermometers and the like are in the market. The present invention relates to an instrument switch triggering mechanism. According to the invention, the trigger signal for opening or closing the instrument can be effectively set, and the sensitivity of instrument switch control is improved.
Procedure for the obtaining of heterociclic compounds, containing a c-acetile group, of formula (I), in which r is a protecting group of amines and amidas or a group arilo; and z is rented. It consists in the reaction of a compound of formula (II) in which r and z are the same as in the formula (I), with dicetano; followed from the treatment of the product obtained with an alkaline alcohol alcohol and iodine or a similar reagent. The reaction with dicetano is carried out in an organic solvent inert at the ebullition temperature of this. The second stage of the reaction is effected in the presence of an excess of alcoholate, in a lower alcanol, at temperature below the environment. > these compounds have pharmacological applications for their antihipoxic properties. (Machine-translation by Google Translate, not legally binding)
Previous studies have shown the relevance of high mobility group box 1 protein (HMGB1) and tumor necrosis factor α (TNFα) in nerve or tissue injury-induced nociception. However, the role of these proteins in chronic stress and social transfer of stress (STS)-induced dysfunctional pain is not entirely known. The aim of this study was to determine the participation of the spinal HMGB1-TNFα signaling pathway and TNFα receptor 1 (TNFR1) in rats subjected to chronic restraint stress (CRS) and STS. Non-stressed female and male rats in contact with CRS rats increased sniffing behavior of the anogenital area, behavior related to STS. Rats subjected to CRS and STS reduced 50 % withdrawal threshold and reached the value of tactile allodynia after 21 days of stress. Rats return to the basal withdrawal threshold after 30 days without stress and return to allodynia values in only 5 days of stress sessions (priming). Female and male rats subjected to 28 days of CRS or STS were intrathecal injected with glycyrrhizin (inhibitor of HMGB1), thalidomide (inhibitor of the TNFα synthesis), and R7050 (TNFR1 antagonist), in all the cases, an antiallodynic effect was observed. Rats under CRS or STS enhanced HMGB1 and TNFR1 protein expression in DRG and dorsal spinal cord. Data suggest that the spinal HMGB1/TNFα/TNFR1 signaling pathway plays a relevant role in the maintenance of CRS and STS-induced nociceptive hypersensitivity in rats. These proteins could be helpful in developing pain treatments for fibromyalgia in humans.
PURPOSE:To cosmetic composition having moisture retention for providing the skin with elasticity and tension, having extremely high moisture retention and extremely high safety, containing at least one extract of Phellodendron amurens, Leguminosae, Scutellaria baicanaceus Georgi, Cindium officinal Makino, etc. as an essential component. CONSTITUTION:A cosmetic composition having moisture retention containing at least one extract of Phellodendron amurens, Leguminosae, Scutellaria baicanaceus Georgi, Cindium officinal Makino, Paeonia lactiflora of the family Paeoniaceae, Paeoniaceae Paenoia moutan Sims of the family Paeoniaceae, Coi lacryma-jobi L. Var. ma-yuen Stapf of the family Gramineae, Angelica dehurica BENTHAM et HOOMER), Aesculus Gurbinate Balune, Ledebouriella seseloides W.) of the family Umbelliferae, Citrus aurantium L. subsp nobils Makino, Geranium thumbergii Sieb. et Zucc., Poria catechu L., Zizius vulgaris Lamarck var. inerimis Bunge, Malva rotundifola Linne, Hypericum erectum Thunberg, Arnica motana L., Galendula officinals L., Sambucus nigra Linne, Hamamelis virginia L., dried R. glutinosa L. var purpurea Makino of the family Schrophulariaceae, dried and steamed R. glutinosa L. var purpurea Makino of the family Schrophulariaceae, and Plantago major L. Var. asatica Decaisne that are useful as a component for common oral internal medicine or food whose safety is confirmed, as an essential component. About 1,000-5,000mg calculated as essence component of the extracted essence is added to a cosmetic composition.
Northern hemisphere freshwater ecosystems are projected to experience significant warming and shortening of winter duration in this century. This change coupled with depletion of oxygen (hypoxia) will result in a shift toward fish species with higher optimal temperatures for growth and reproduction that can mitigate hypoxic stress. Here, we tested the assumption that reproduction between two distant species, i.e. anoxic-intolerant common carp (Cyprinus carpio) and anoxic-tolerant goldfish (Carassius auratus), results in the expression of genes responsible for ethanol synthesis (alcohol dehydrogenase and pyruvate dehydrogenase subunit E1β2). The expression of this ethanol-producing pyruvate decarboxylase pathway may transform the biochemical characteristics of progeny into anoxic-tolerant hybrids, expanding their suitable environmental range and potentially increasing invasiveness. Concurrently, a genetic strategy for improving fish tolerance to oxygen-depleted environments will be a valuable physiological trait in fish culture. Differential quantification of gene expression by analyzing mRNA revealed that, compared with koi×koi, koi female×goldfish male (F1 hybrid) possessed the pyruvate dehydrogenase subunit E1β2 gene construct, which was expressed at significantly greater levels in red muscle. The potential of this hybrid to both survive in extreme anoxic conditions and grow at elevated water temperatures would likely contribute to their ecological success.
Participants began taking placebo to match armodafinil and following the same titration procedure. Treatment was administered for a total of 8 weeks.
There are currently no effective biomarkers to select chemotherapy, immunotherapy, and radiotherapy for treating lung cancer patients. This study identified genetic networks containing major immune-checkpoint inhibitors  CD27, PD1 , and  PDL1 , and their associated prognostic genes and proliferation genes in lung cancer tumors. A co-expression network that was missing in tumor B cells was discovered that can promote lung cancer proliferation. A 5-gene and a 9-gene prognostic models were developed and validated in extensive cohorts to select patients at a high risk for developing metastasis. CRISPR-Cas9 and RNA interference screening data were used in the selection of proliferation genes. These genes were associated with chemoresponse and radiotherapy response in lung cancer cell lines and patient tumors. These immune-omics networks led to the discovery of repositioning drugs for improving lung cancer treatment.
Osteosarcoma, the most common primary bone cancer that affects adolescents worldwide, has the early metastatic potential to be responsible for high mortality rates. Morin has a multipurpose role in numerous cancers, whereas little is known about its role in osteosarcoma migration and invasion. Therefore, we hypothesized that morin suppresses the invasive activities and the migratory potential of human osteosarcoma cells. Our results showed that morin reduced migration and invasion capabilities in human osteosarcoma U2OS and HOS cells. Moreover, morin inhibited the urokinase plasminogen activator (uPA) expression through a signal transducer and an activator of transcription-3 (STAT3) phosphorylation. After STAT3 overexpression, the decrease of the migratory potential and uPA expression caused by 100 μM of morin in U2OS cells was countered, indicating that STAT3 contributes to the antimetastatic property of morin in human osteosarcoma cells by reducing uPA. In conclusion, morin may be a potential candidate for the antimetastatic treatment of human osteosarcoma.
INTRODUCTION: Hand hygiene in nurses is the most effective factor in controlling nosocomial infections. The objective of this study was to assess the effectiveness of motivational interviews and teach-back on the rate of hand hygiene compliance in Intensive Care Unit nurses.
METHODS: A quasi-experimental study with pre-test and post-test design was performed. Three Intensive Care Units with 88 nurses were randomly divided into three study groups. The control group received only the usual hospital teaching in hand hygiene, the experimental groups 1 and 2, in addition to the usual teaching, they received motivational interview and teach back in five weekly sessions, respectively. The rate of hand hygiene compliance in nurses was measured by Hand Hygiene Practices Inventory.
RESULTS: There was a statistically significant difference for the rate of hand hygiene compliance before and after the intervention in the study groups with p < 0.001. In comparison before and after, in experimental group 1, the rate of hand rub increased from 8% to 18.5% and the rate of hand wash from 1.5% to 22%; and in the experimental group 2, these values increased from 4% to 19.5% in hand rub and from 3.5% to 17% in hand wash, respectively. However, in the control group, the rate of hand hygiene compliance before and after the test did not show a statistically significant difference with p > 0.05.
CONCLUSIONS: Motivational interview and teach back methods were effective in promoting hand hygiene compliance in nurses and thus improve the control of nosocomial infections.
Subjects will receive a single 100 mg oral tablet of glasdegib under fasted conditions in the first study period followed by washout. Then in the second period, a 50 mg IV solution will be infused over approximately 1.25 hours under fasted conditions.
Cryptococcal meningitis is an important cause of disease and death among patients with AIDS. Usually AMB is given either alone or with FLC to patients with this infection, but these treatments are not always effective and both have toxic effects. Animal studies and preliminary studies in humans show that FCZ is active in cryptococcal meningitis and suggest that it may be less toxic than either AMB or FLC.

Patients accepted into the study are randomly assigned to FCZ or AMB. Patients assigned to FCZ take FCZ by mouth daily for 10 weeks. Patients assigned to AMB are given intravenous injections of AMB daily for 6-10 weeks. Non-AIDS patients assigned to AMB also take FLC by mouth daily. The use of FLC in patients with AIDS is decided on an individual basis. Patients with AIDS who respond satisfactorily to FCZ receive maintenance therapy to prevent relapse for an additional 12 months. Patients with AIDS who respond to AMB may qualify for another Pfizer Central Research protocol. Patients without AIDS who respond to therapy are observed for 6 months for relapse. During therapy, samples of blood and cerebrospinal fluid (by lumbar puncture) are taken periodically in order to evaluate the effectiveness of the drug treatments and to identify possible toxic effects.
BACKGROUND: The prevalence of obesity has been increasing worldwide and is associated with increased risk of morbidity and mortality. Weight management can reduce the risk of complications and improve the quality of life of patients with obesity. This study explored primary care physicians' (PCPs') attitudes and knowledge about weight management.
METHODS: An anonymous questionnaire was distributed to 400 PCPs between 2020 and 2021. The survey included questions on treatment approaches (pharmaceutical and surgical) and items regarding the respondents' demographic characteristics. We compared PCPs with low or high proactivity toward weight management. We explored attitudes and knowledge with the chi-square test for categorical variables or the Mann-Whitney test for continuous variables.
RESULTS: A total of 145 PCPs answered our survey (a response rate of 36.25%). More than half (53.8%) of the respondents showed low proactivity toward weight management in their practice. Proactive respondents were more likely to believe that pharmaceutical treatment effectively reduces weight and offered medical and surgical treatment options more frequently to their patients. Lack of knowledge was the most predominant reason for PCPs avoiding offering treatment to their patients, especially in less proactive PCPs (33.3% vs. 5.3%, p-value < 0.001). When comparing different pharmaceutical options, 46.6% of PCPs report they tend to prescribe liraglutide to their patients compared with only 11% who prescribe orlistat and 10.3% who prescribe phentermine (p-value < 0.001).
CONCLUSIONS: Many PCPs still do not actively provide obesity treatment despite improved awareness and therapeutic options. PCPs' proactivity and attitudes are vital to this effort.
This is a single center, investigator-blinded (investigator masked), head to head comparison of Restasis® and its vehicle, Refresh® Dry Eye Therapy in 24 patients. Three target fingernails will be identified in each subject. Two of the target nails will be the two nails that have the most severe signs of brittle nail syndrome. The third target nail will be a normal nail or, in the absence of a normal nail, the patient's second-healthiest appearing nail. The patients most normal-appearing nail will be untreated so that growth in the treated nails can be compared to growth in an untreated normal nail, this will be the fourth target nail. Study medication will be applied to target nails (the subjects may also apply to all nails if they wish, except one nail which will be untreated in order to determine the subject's baseline rate of fingernail growth) for 24 weeks. The target nails will be assessed at each visit, every four weeks. There will be a 12-week follow up period after treatment is completed.

This 36 week study will be conducted at one center. Adult male and female patients meeting the inclusion and exclusion criteria will be screened for eligibility. The principal investigator or his/her designee will obtain informed consent from all patients before any protocol specific procedures are performed.
Automated modular physical health testing systems and associated devices and methods are disclosed herein. A modular system configured in accordance with embodiments of the present technology can include, for example, a housing, a communications hub, and a plurality of physical health testing devices. The housing integrates the communications hub and stores the plurality of physical health testing devices. The physical health testing devices are in wired and/or wireless communication with the communications hub. Each physical health testing device is configured to generate physical health data of a user and to transmit generated physical health data to the communication hub and/or a user's mobile device. The modular physical health testing system provides an automated physical exam that can be performed at user's homes or other convenient locations.
PURPOSE:To form a substrate sheet extremely thin and to prevent the sheet from being shrunk or extended, etc., at the time of adhesion work by forming a skin side adhesive agent layer on a lower surface to the substrate sheet which is composed of soft materials, adhering a peeling paper on an external surface and laminating an aqueous form keeping sheet on the upper surface of the substrate sheet. CONSTITUTION:For a skin adhesive tape 1, a skin side adhesive agent layer 3 of a special silicone pressure sensitive adhesive agent layer, etc., is formed on the lower surface to a substrate sheet 2 to be composed of the soft materials such as a thin film latex film, etc., to have the thickness of 30mum, for example. Then, a peeling paper 4 is adhered and laminated on the external surface. On the other hand, a form keeping sheet 5 to be composed of the aqueous material such as aqueous protein, aqueous resin and an aqueous paper, etc., is strongly pressed to a film shape, which has suitable rigidity, adhered and laminated on the upper surface in order to keep the form of the substrate sheet 2. When the tape is attached to a body, the peeling paper 4 is peeled off and the form keeping sheet 5 is attached and grasped as the base of operation. Then, when the skin side adhesive agent layer 3 is adhered to a correspondent part along the skin surface of the body, the substrate sheet 2 can be easily attached.
Atopic dermatitis has a substantial impact on sleep, appearance, psychological well-being, and other qualities of life. The visual appearance of lichenification, cheilitis, hyperpigmentation, ichthyosis, and erythema can be socially stigmatizing, and treatment of these symptoms is challenging. In managing pruritus in patients, practitioners should assess and document pruritus through questionnaires at each routine visit. Initially, practitioners should advise patients to employ nonpharmaceutical treatments such as emollients with wet wraps, elimination of triggers, changing scratching habits, and psychological interventions. If these methods of treatment are not successful or if the disease presentation is severe, pharmacological therapies should be employed. This chapter describes the therapeutic ladder for pruritus in atopic dermatitis and discusses each treatment modality in further detail for practitioners to advise their patients.First-line topical pharmaceutical agents include topical glucocorticoids and topical calcineurin inhibitors. Second-line topical agents include coal tar, menthol, capsaicin, or doxepin. After the use of topical agents has been exhausted, primary systemic agents can be applied. These include sedating antihistamines, nonsedating antihistamines, oral glucocorticoids, or cyclosporine A. Finally, neuromodulating or immunomodulating agents can be attempted, including SSRI/SNRIs, TCAs, immunosuppressants, neural modulators, and opioid receptor modulators. Outside of pharmacological treatments, phototherapy has been shown to provide a dramatic improvement of pruritus in atopic dermatitis and can be used at any stage of treatment including as a first-line agent.
PCT No. PCT/JP82/00385 Sec. 371 Date May 13, 1983 Sec. 102(e) Date May 13, 1983 PCT Filed Sep. 24, 1982 PCT Pub. No. WO83/01000 PCT Pub. Date Mar. 31, 1983.A composition capable of promoting the skin permeation or percutaneous absorption of a drug, which comprises a lower alcohol and at least one member of the group consisting of a saturated aliphatic hydrocarbon containing 5 to 20 carbon atoms, which may optionally be halogen-substituted, a monohydric alcohol ester of an aliphatic carboxylic acid, which contains 13 to 24 carbon atoms, and an ether containing 8 to 16 carbon atoms with one ether bondage in the molecule; and an external preparation containing the above composition as a base.
A patient in her 50s presented with altered mental status and shortness of breath at 4600 m elevation. After descent to the base of the mountain, the patient became comatose. She was found to have bilateral pulmonary infiltrates and a serum sodium of 102 mEq/L. She was rapidly corrected to 131 mEq/L in 1 day. Initial MRI showed intensities in bilateral hippocampi, temporal cortex and insula. A repeat MRI 17 days post injury showed worsened intensities in the bilateral occipital lobes. On admission to acute rehabilitation, the patient presented with blindness, agitation, hallucinations and an inability to follow commands. Midway through her rehabilitation course, antioxidant supplementations were started with significant improvement in function. Rapid correction of hyponatraemia may cause central pontine myelinolysis or extrapontine myelinolysis (EPM). In some cases of hypoxic brain injury, delayed post-hypoxic leucoencephalopathy (DPHL) may occur. Treatment options for both disorders are generally supportive. This report represents the only documented interdisciplinary approach to treatment of a patient with DPHL and EPM. Antioxidant supplementation may be beneficial as a treatment option for both EPM and DPHL.
Participants will be recruited either through clinics at the functional gut clinic or through interest shown to advertising for the study. If the patient is deemed eligible they will be given atleast 24 hours to review the patient information sheet. If they would like to proceed with participation they will be given the chance to ask the study team any questions. If they would still like to proceed the participant will be asked to sign three copies of the informed consent form.

The participants will be required to visit the clinic twice during the study. The day before visit 1 the patient will be required to follow a low residue diet as part of preparation for the hydrogen methane breath. On the day of the first visit participants will complete a hydrogen methane breath test as per the functional gut clinics test protocol, the patient will also be asked to fill two questionnaires about their symptoms. Participants will then be provided with a 10 day bowel and symptom diary and a 10 day supply of blinded the intestinal adsorbent . Participants will be provided with instructions on how to take the the study product and training on completing their daily diary. They will be required to take the study product for 10 consecutive days according to manufacturers instructions.

Participants will return for the second and final visit on the final day of consuming the study product. The day before visit 2 the patient will be required to follow a low residue diet as part of preparation for the hydrogen methane breath. On the day of the second visit participants will complete a hydrogen methane breath test as per the functional gut clinics test protocol, the patient will also be asked to fill two questionnaires about their symptoms. Once these study procedures are complete the participants will have finished their participation in the study.